Cholinesterase inhibitors and Alzheimer's disease outcomes

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 62, Issue 5, 2007, Pages 570-

  Garcia, Angeles ^a,b   Thompson, Kelli ^a   Zanibbi, Katherine ^a   Geick, Shannon ^a   Adams, Rachel ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b St Mary's of the Lake   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; LETTER; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 34447519203     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/62.5.570     Document Type: Letter

References (5)

1. Gillette-Guyonnet S, Andrieu S, Cortes F, et al. Outcome of Alzheimer's disease: Potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci. 2006;61A:516-520.
2. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc. 2002;50:35-40.
3. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310-314.
4. Loy C, Schneider L. Galantamine for Alzheimers's disease and mild cognitive impairment. Cochrane Database System Reviews. 2006; Issue 1, Art. No.: CD001747.pub3. DOI: 10.1002/14651858.CD001747.pub3.
5. Schaufele M, Bickel H, Weyerer S. Predictors of mortality among demented elderly in primary care. Int J Geriatr Psychiatry. 1999; 14:946-956.